Early Results of Surgery in 123 Patients with Pseudomyxoma Peritonei from a Perforated Appendiceal Neoplasm

Murphy, Elizabeth; Sexton, Rosemary; Moran, Brendan

doi:10.1007/s10350-006-0741-9

Cited by 63 publications

(35 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was a 96% and 43% 5 year overall survival and progression-free survival, respectively. Grade 2 or 3 complications occurred 33% of the time, and this is keeping with the literature, which reports a morbidity rate of 24-45% [10,17,21,23,24] and mortality rates of 1.6-5% [11,21,23,25,26]. Again demonstrating prolonged survival with combination of cytoreductive surgery and HIPEC.…”

Section: Journal Of Gastrointestinal and Digestive Systemsupporting

confidence: 86%

“…Many studies show 5-year overall survival rates that are improved with cytoreductive surgery and HIPEC, when compared to cytoreductive surgery alone, 53-100% versus 53-75%, respectively [7,9,15,17,19,[21][22][23][26][27][28][29][30][31]. Despite these results, there have been no randomized controlled trials comparing cytoreductive surgery and cytoreductive surgery with HIPEC in patients with low-grade appendiceal neoplasms.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The Role of Heated Intraperitoneal Chemotherapy (HIPEC) in Low-Grade Appendiceal Neoplasm: Friend or Foe?

Porpiglia¹,

Nguyen²,

Farma³

et al. 2016

J Gastrointest Dig Syst

View full text Add to dashboard Cite

Low-grade mucinous appendiceal neoplasms are rare tumors. There is limited data on the treatment for pseudomyxoma peritonei with low-grade appendiceal histology. Classifications of appendiceal neoplasms include low-grade appendiceal mucinous neoplasm (LAMN), diffuse peritoneal adenomucinosis (DPAM), and peritoneal mucinous carcinomatosis (PMCA). Studies have demonstrated patients with low-grade appendiceal neoplasms have improved overall survival compared to patients with high-grade appendiceal neoplasms. Since low-grade tumors have better prognosis some retrospective trials have suggested observation in patients with these types of tumors. Another option includes cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). We have done an extensive literature search exploring the various methods in which to treat patients with this disease.

show abstract

Section: Journal Of Gastrointestinal and Digestive Systemsupporting

confidence: 86%

Section: Resultsmentioning

confidence: 99%

The Role of Heated Intraperitoneal Chemotherapy (HIPEC) in Low-Grade Appendiceal Neoplasm: Friend or Foe?

Porpiglia¹,

Nguyen²,

Farma³

et al. 2016

J Gastrointest Dig Syst

View full text Add to dashboard Cite

show abstract

“…The optimal treatment of PMP involves extensive cytoreductive surgery (Table 1) and intraperitoneal chemotherapy with a five year survival rate of 70 to 80% [15][16][17][18][19]. However this complex treatment may impact significantly on the patients quality of life, especially the many in whom complete tumour removal is not achieved.…”

Section: Discussionmentioning

confidence: 99%

Prospective longitudinal study of quality of life following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei

Alves

Mohamed

Yadegarfar

et al. 2010

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“…Disease features that prohibit complete cytoreduction include gastric encasement, diffuse small bowel mesenteric involvement and fistulation (Sugarbaker and Chang, 1999). For such advanced unresectable cases, debulking surgery may offer symptomatic relief, but is associated with considerable morbidity and mortality (Murphy et al, 2007;Smeenk et al, 2007).…”

mentioning

confidence: 99%

A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei

et al. 2008

View full text Add to dashboard Cite

Pseudomyxoma peritonei (PMP) is a rare neoplastic process characterised by progressive intra-abdominal dissemination of mucinous tumour, and generally considered resistant to systemic chemotherapy. A phase II study in patients with advanced unresectable PMP was undertaken to evaluate the combination of systemic concurrent mitomycin C (7 mg m À2 i.v. on day 1) and capecitabine (1250 mg m À2 b.d. on days 1 -14) in a 3-weekly cycle (MCap). Response was determined by semiquantitative assessment of disease volume on serial computed tomographic (CT) scans and serum tumour marker (CEA, CA125, CA19-9) changes at 12 weeks. Between 2003 and 2006, 40 patients were recruited through a national centre for the treatment of peritoneal surface tumours. At baseline, 23 patients had progressive disease and 17 had stable disease. Of 39 assessable patients, 15 (38%, 95% confidence intervals (CIs): 25, 54%) benefited from chemotherapy in the form of either reductions in mucinous deposition or stabilisation of progressive pretreatment disease determined on CT scan. Notably, two patients, originally considered unresectable, following MCap and re-staging underwent potentially curative cytoreductive surgery. Grade 3/4 toxicity rates were low (6%, 95% CIs: 4, 9%). Twenty out of 29 assessed patients (69%, 95% CIs: 51, 83%) felt that their Global Health Status improved during chemotherapy. This is the first trial to demonstrate an apparent benefit of systemic chemotherapy in patients with advanced unresectable PMP.

show abstract

Early Results of Surgery in 123 Patients with Pseudomyxoma Peritonei from a Perforated Appendiceal Neoplasm

Abstract: A perforated appendiceal epithelial tumor most frequently presents as pseudomyxoma peritonei. This treatment strategy, involving surgery and intraperitoneal chemotherapy, can result in good outcomes in this rare and otherwise fatal disease.

Cited by 63 publications

References 30 publications

The Role of Heated Intraperitoneal Chemotherapy (HIPEC) in Low-Grade Appendiceal Neoplasm: Friend or Foe?

The Role of Heated Intraperitoneal Chemotherapy (HIPEC) in Low-Grade Appendiceal Neoplasm: Friend or Foe?

Prospective longitudinal study of quality of life following cytoreductive surgery and intraperitoneal chemotherapy for pseudomyxoma peritonei

A phase II study evaluating the use of concurrent mitomycin C and capecitabine in patients with advanced unresectable pseudomyxoma peritonei

Contact Info

Product

Resources

About